Feasibility of Use of Indocyanine Green in Pediatric Colorectal Surgery

PHASE3RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

July 31, 2024

Conditions
Hirschsprung DiseaseAnorectal Malformations
Interventions
DRUG

Indocyanine green

The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).

Trial Locations (1)

N6A5W9

RECRUITING

Children's Hospital, London Health Sciences Centre, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER